Beckman Coulter sponsored 2nd World Sepsis Congress

World Sepsis Day 2018

Beckman Coulter sponsored 2nd World Sepsis Congress

Beckman Coulter was a gold sponsor of the 2nd World Sepsis Congress, a free-of-charge online conference, hosted by the Global Sepsis Alliance, that took place on Sept. 5 and 6, 2018. Over the course of 17 sessions, more than 100 speakers from approximately 30 countries discussed the wide-ranging implications of sepsis and how to raise public awareness of this often-fatal condition.

Sepsis affects 26 million people worldwide each year, and is increasing at a rate of 1.5 percent annually. In the United States alone, about 1.6 million people are diagnosed with the disease. Additionally, it is the third leading cause of death, claiming more than 258,000 lives in the U.S. each year. “Sepsis is one of the world's deadliest diseases that often goes undiagnosed,” said Peter Soltani, Ph.D., senior vice president and general manager of Beckman Coulter's hematology business. “As many as 80 percent of sepsis deaths could be prevented with rapid diagnosis and treatment.”

“We were proud to be a sponsor of the 2nd World Sepsis Congress,” said Soltani, “since its goals align perfectly with our commitment to empowering healthcare professionals with the tools and resources that enable them to detect sepsis as early as possible during patient care.”

Delayed treatment of sepsis can cause cardiovascular collapse, tissue damage, organ failure and ultimately death. Even patients with less severe sepsis can progress to the more severe condition, septic shock, within 72 hours, and up to half of those patients will die as a result. Timely and accurate detection solutions, in an acute-care setting where treatment can be initiated, are key components to stopping the progression of the disease. In fact, when antibiotics are administered early to patients with septic shock, the likelihood of death decreases by 7.6 percent per hour.

In answer to the urgent need for a fast and an accurate detection solution, in June of this year, Beckman Coulter filed a submission for 510(k) clearance with the U.S. Food and Drug Administration for its Early Sepsis Indicator, a hematology-based solution designed to alert emergency room clinicians to any patient who might possibly be at risk for developing sepsis. It recently achieved European CE Mark, and is commercially available in select countries for use with the company's DxH 900 hematology analyzer, which was released in May 2018.

Beckman Coulter continues to lead innovation in clinical diagnostics with investment in research and development targeted to areas―such as markers for diseases that pose the greatest threat to a long and healthy life―that can dramatically improve patient care and reduce the cost to manage prevalent diseases.

Source: Beckman Coulter

11.09.2018

Read all latest stories

Related articles

Photo

Catheter systems

Ousting out-dated recommendations

Recommendations on the currently valid prevention of intravascular catheter-related infections from the Commission for Hospital Hygiene and Infection Prevention at the Robert Koch-Institute (KRINKO)…

Photo

Prevention

Specimen diversion devices lower blood culture contamination

Blood cultures are among the most important laboratory tests a patient can have, especially to diagnose serious infections. Contamination is a constant concern – a patient could be misdiagnosed due…

Photo

Hematology

Early sepsis indicator helps identifying patients at risk

The critical element of testing for sepsis lies not so much in the location but in the timing and rapidity of results, according to Professor Jeannine T. Holden from Beckman Coulter Early…

Related products

Beckman Coulter – DxH 690T

Blood Cell Counter

Beckman Coulter – DxH 690T

Beckman Coulter, Inc.
Lifotronic - FA-160 Immunofluorescence Analyzer

Other

Lifotronic - FA-160 Immunofluorescence Analyzer

Lifotronic Technology Co., Ltd
Alsachim, a Shimadzu group company – Dosinaco

Clinical Chemistry

Alsachim, a Shimadzu group company – Dosinaco

Alsachim, a Shimadzu Group Company
ASP Lab Automation – Recapper KapSafe

Sample Processing

ASP Lab Automation – Recapper KapSafe

ASP Lab Automation AG
Subscribe to Newsletter